Literature DB >> 31578870

Mitochondrial Dysfunction at the Center of Cancer Therapy.

Hsin Yao Chiu1, Emmy Xue Yun Tay1, Derrick Sek Tong Ong1, Reshma Taneja1.   

Abstract

Significance: Mitochondria undergo constant morphological changes through fusion, fission, and mitophagy. As the key organelle in cells, mitochondria are responsible for numerous essential cellular functions such as metabolism, regulation of calcium (Ca2+), generation of reactive oxygen species, and initiation of apoptosis. Unsurprisingly, mitochondrial dysfunctions underlie many pathologies including cancer. Recent Advances: Currently, the gold standard for cancer treatment is chemotherapy, radiation, and surgery. However, the efficacy of these treatments varies across different cancer cells. It has been suggested that mitochondria may be at the center of these diverse responses. In the past decade, significant advances have been made in understanding distinct types of mitochondrial dysfunctions in cancer. Through investigations of underlying mechanisms, more effective treatment options are developed. Critical Issues: We summarize various mitochondria dysfunctions in cancer progression that have led to the development of therapeutic options. Current mitochondrial-targeted therapies and challenges are discussed. Future Directions: To address the "root" of cancer, utilization of mitochondrial-targeted therapy to target cancer stem cells may be valuable. Investigation of other areas such as mitochondrial trafficking may offer new insights into cancer therapy. Moreover, common antibiotics could be explored as mitocans, and synthetic lethality screens can be utilized to overcome the plasticity of cancer cells.

Entities:  

Keywords:  apoptosis; calcium; cancer therapy; mitochondria; mitochondria-associated ER membranes (MAMs); mitochondrial dynamics; reactive oxygen species (ROS)

Mesh:

Substances:

Year:  2019        PMID: 31578870     DOI: 10.1089/ars.2019.7898

Source DB:  PubMed          Journal:  Antioxid Redox Signal        ISSN: 1523-0864            Impact factor:   8.401


  17 in total

Review 1.  Mitochondria-Targeted, Nanoparticle-Based Drug-Delivery Systems: Therapeutics for Mitochondrial Disorders.

Authors:  Sakshi Buchke; Muskan Sharma; Anusuiya Bora; Maitrali Relekar; Piyush Bhanu; Jitendra Kumar
Journal:  Life (Basel)       Date:  2022-04-29

2.  Hesperadin suppresses pancreatic cancer through ATF4/GADD45A axis at nanomolar concentrations.

Authors:  Yixuan Zhang; Jianzhuang Wu; Yao Fu; Ranran Yu; Haochen Su; Qisi Zheng; Hao Wu; Siqi Zhou; Kun Wang; Jing Zhao; Shanshan Shen; Guifang Xu; Lei Wang; Chao Yan; Xiaoping Zou; Ying Lv; Shu Zhang
Journal:  Oncogene       Date:  2022-05-12       Impact factor: 8.756

3.  Integrative multiplatform-based molecular profiling of human colorectal cancer reveals proteogenomic alterations underlying mitochondrial inactivation.

Authors:  Wei Zhang; Donge Tang; Liewen Lin; Tingting Fan; Ligang Xia; Wanxia Cai; Weier Dai; Chang Zou; Lianghong Yin; Yong Xu; Yong Dai
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

4.  lncRNA DLX6-AS1 Promotes Proliferation of Laryngeal Cancer Cells by Targeting the miR-26a/TRPC3 Pathway.

Authors:  Yan Liu; Xinyi Liu; Xiaofeng Zhang; Jinhu Deng; Jian Zhang; Hao Xing
Journal:  Cancer Manag Res       Date:  2020-04-21       Impact factor: 3.989

Review 5.  Mitocanic Di- and Triterpenoid Rhodamine B Conjugates.

Authors:  Sophie Hoenke; Immo Serbian; Hans-Peter Deigner; René Csuk
Journal:  Molecules       Date:  2020-11-20       Impact factor: 4.411

Review 6.  Updated Understanding of Cancer as a Metabolic and Telomere-Driven Disease, and Proposal for Complex Personalized Treatment, a Hypothesis.

Authors:  Cristian Muresanu; Siva G Somasundaram; Sergey V Vissarionov; Luis Fernando Torres Solis; Arturo Solís Herrera; Cecil E Kirkland; Gjumrakch Aliev
Journal:  Int J Mol Sci       Date:  2020-09-07       Impact factor: 5.923

7.  Ref-1 redox activity alters cancer cell metabolism in pancreatic cancer: exploiting this novel finding as a potential target.

Authors:  Silpa Gampala; Fenil Shah; Xiaoyu Lu; Hye-Ran Moon; Olivia Babb; Nikkitha Umesh Ganesh; George Sandusky; Emily Hulsey; Lee Armstrong; Amber L Mosely; Bumsoo Han; Mircea Ivan; Jing-Ruey Joanna Yeh; Mark R Kelley; Chi Zhang; Melissa L Fishel
Journal:  J Exp Clin Cancer Res       Date:  2021-08-10

8.  MAPK1/3 kinase-dependent ULK1 degradation attenuates mitophagy and promotes breast cancer bone metastasis.

Authors:  Rong Deng; Hai-Liang Zhang; Jun-Hao Huang; Rui-Zhao Cai; Yan Wang; Yu-Hong Chen; Bing-Xin Hu; Zhi-Peng Ye; Zhi-Ling Li; Jia Mai; Yun Huang; Xuan Li; Xiao-Dan Peng; Gong-Kan Feng; Jun-Dong Li; Jun Tang; Xiao-Feng Zhu
Journal:  Autophagy       Date:  2020-12-07       Impact factor: 16.016

Review 9.  Mitochondrial Ca2+ Signaling in Health, Disease and Therapy.

Authors:  Lorenzo Modesti; Alberto Danese; Veronica Angela Maria Vitto; Daniela Ramaccini; Gianluca Aguiari; Roberta Gafà; Giovanni Lanza; Carlotta Giorgi; Paolo Pinton
Journal:  Cells       Date:  2021-05-25       Impact factor: 6.600

10.  Pink1/PARK2/mROS-Dependent Mitophagy Initiates the Sensitization of Cancer Cells to Radiation.

Authors:  Lei Yu; Xiangshan Yang; Xin Li; Lijing Qin; Weiqiang Xu; Hongli Cui; Zhen Jia; Qiang He; Zhicheng Wang
Journal:  Oxid Med Cell Longev       Date:  2021-07-06       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.